These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
176 related articles for article (PubMed ID: 9202045)
41. Presence of active gelatinases in endometrial carcinoma and correlation of matrix metalloproteinase expression with increasing tumor grade and invasion. Di Nezza LA; Misajon A; Zhang J; Jobling T; Quinn MA; Ostör AG; Nie G; Lopata A; Salamonsen LA Cancer; 2002 Mar; 94(5):1466-75. PubMed ID: 11920503 [TBL] [Abstract][Full Text] [Related]
42. Differential expression of membrane-type matrix metalloproteinase and its correlation with gelatinase A activation in human malignant brain tumors in vivo and in vitro. Yamamoto M; Mohanam S; Sawaya R; Fuller GN; Seiki M; Sato H; Gokaslan ZL; Liotta LA; Nicolson GL; Rao JS Cancer Res; 1996 Jan; 56(2):384-92. PubMed ID: 8542596 [TBL] [Abstract][Full Text] [Related]
43. Temporal expression of extracellular matrix metalloproteinases and tissue plasminogen activator in the development of collateral vessels in the canine model of coronary occlusion. Tyagi SC; Kumar S; Cassatt S; Parker JL Can J Physiol Pharmacol; 1996 Aug; 74(8):983-95. PubMed ID: 8960389 [TBL] [Abstract][Full Text] [Related]
44. Purification and characterization of matrix metalloproteinase 9 from U937 monocytic leukaemia and HT1080 fibrosarcoma cells. Morodomi T; Ogata Y; Sasaguri Y; Morimatsu M; Nagase H Biochem J; 1992 Jul; 285 ( Pt 2)(Pt 2):603-11. PubMed ID: 1379048 [TBL] [Abstract][Full Text] [Related]
45. Mast cell proteinases activate precursor forms of collagenase and stromelysin, but not of gelatinases A and B. Lees M; Taylor DJ; Woolley DE Eur J Biochem; 1994 Jul; 223(1):171-7. PubMed ID: 8033891 [TBL] [Abstract][Full Text] [Related]
46. Expression of matrix metalloproteinases during murine chorioallantoic placenta maturation. Teesalu T; Masson R; Basset P; Blasi F; Talarico D Dev Dyn; 1999 Mar; 214(3):248-58. PubMed ID: 10090151 [TBL] [Abstract][Full Text] [Related]
47. Augmented membrane type 1 matrix metalloproteinase (MT1-MMP):MMP-2 messenger RNA ratio in gastric carcinomas with poor prognosis. Caenazzo C; Onisto M; Sartor L; Scalerta R; Giraldo A; Nitti D; Garbisa S Clin Cancer Res; 1998 Sep; 4(9):2179-86. PubMed ID: 9748137 [TBL] [Abstract][Full Text] [Related]
48. Cell surface binding and activation of gelatinase A induced by expression of membrane-type-1-matrix metalloproteinase (MT1-MMP). Sato H; Takino T; Kinoshita T; Imai K; Okada Y; Stetler Stevenson WG; Seiki M FEBS Lett; 1996 May; 385(3):238-40. PubMed ID: 8647259 [TBL] [Abstract][Full Text] [Related]
49. Activation of matrix metalloproteinase-9 (MMP-9) via a converging plasmin/stromelysin-1 cascade enhances tumor cell invasion. Ramos-DeSimone N; Hahn-Dantona E; Sipley J; Nagase H; French DL; Quigley JP J Biol Chem; 1999 May; 274(19):13066-76. PubMed ID: 10224058 [TBL] [Abstract][Full Text] [Related]
50. Remodeling of collagen matrix by human tumor cells requires activation and cell surface association of matrix metalloproteinase-2. Deryugina EI; Bourdon MA; Reisfeld RA; Strongin A Cancer Res; 1998 Aug; 58(16):3743-50. PubMed ID: 9721888 [TBL] [Abstract][Full Text] [Related]
51. Modulation of neutral protease expression in human mesangial cells by hyperglycaemic culture. Abdel Wahab N; Mason RM Biochem J; 1996 Dec; 320 ( Pt 3)(Pt 3):777-83. PubMed ID: 9003362 [TBL] [Abstract][Full Text] [Related]
53. Effects of nonsteroidal anti-inflammatory drugs on the expression of urokinase plasminogen activator and inhibitor and gelatinases in the early osteoarthritic knee of humans. Yang SF; Hsieh YS; Lue KH; Chu SC; Chang IC; Lu KH Clin Biochem; 2008 Jan; 41(1-2):109-16. PubMed ID: 17996201 [TBL] [Abstract][Full Text] [Related]
54. The differential regulation and secretion of proteinases from fetal and neonatal fibroblasts by growth factors. Cullen B; Silcock D; Brown LJ; Gosiewska A; Geesin JC Int J Biochem Cell Biol; 1997 Jan; 29(1):241-50. PubMed ID: 9076959 [TBL] [Abstract][Full Text] [Related]
55. The cleavage of pro-urokinase type plasminogen activator by stromelysin-1. Orgel D; Schröder W; Hecker-Kia A; Weithmann KU; Kolkenbrock H; Ulbrich N Clin Chem Lab Med; 1998 Sep; 36(9):697-702. PubMed ID: 9804393 [TBL] [Abstract][Full Text] [Related]
57. Altered balance between matrix metalloproteinases and their inhibitors in experimental biliary fibrosis. Kossakowska AE; Edwards DR; Lee SS; Urbanski LS; Stabbler AL; Zhang CL; Phillips BW; Zhang Y; Urbanski SJ Am J Pathol; 1998 Dec; 153(6):1895-902. PubMed ID: 9846979 [TBL] [Abstract][Full Text] [Related]
58. Suppression of in vitro invasion of human fibrosarcoma cells by a leupeptin analogue inhibiting the urokinase-plasmin system. Kawada M; Umezawa K Biochem Biophys Res Commun; 1995 Apr; 209(1):25-30. PubMed ID: 7726842 [TBL] [Abstract][Full Text] [Related]
59. Enhanced expression of interstitial collagenase, stromelysin-1, and urokinase plasminogen activator in lesions of dermatitis herpetiformis. Airola K; Vaalamo M; Reunala T; Saarialho-Kere UK J Invest Dermatol; 1995 Aug; 105(2):184-9. PubMed ID: 7636299 [TBL] [Abstract][Full Text] [Related]
60. Binding of latent matrix metalloproteinase 9 to fibrin: activation via a plasmin-dependent pathway. Makowski GS; Ramsby ML Inflammation; 1998 Jun; 22(3):287-305. PubMed ID: 9604716 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]